William J Gradishar, MD
Baek SY et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: An 8-year follow-up of the ASTRRA trial. J Clin Oncol 2023;41(31):4864-71. Abstract
Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol 2023;41(7):1370-5. Abstract
Gray RG et al. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. ASCO 2023;Abstract.
Erica Mayer, MD, MPH, FASCO
Azim H et al. Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy. San Antonio Breast Cancer Symposium 2023;Abstract GS2-07.
Kabirian R et al. Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer. JAMA Netw Open 2023;6(11):e234910. Abstract
Partridge AH et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med 2023;388(18):1645-56. Abstract
Virginia Kaklamani, MD, DSc
Cucciniello L et al. Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome. Treat Revs 2023;120:102624. Abstract
Lambertini M et al. Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy. Am Soc Clin Oncol Educ Book 2023;34e390442. Abstract
Leonard RCF et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Ann Oncol 2017;28(8):1811-6. Abstract
Parker WH et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2023;121(4):709-16. Abstract
Rocca WA et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy: A population-based cohort study. Mayo Clin Proc 2016;91(11):1577-89. Abstract
Seth Wander, MD, PhD
Baek SY et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: An 8-year follow-up of the ASTRRA trial. J Clin Oncol 2023;41(31):4864-71. Abstract
McCann KE et al. Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ Breast Ca 2024;10(8). Abstract
Sheen M et al. Administration of goserelin at alternative anatomical sites in premenopausal breast cancer. NCCN National Conference 2024;Abstract CLO24-065.